Sugi Predict

Sugi Predict / Compounds / SCHEMBL30653448

SCHEMBL30653448

SCHEMBL30653448

CC(=O)N[C@H]1[C@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@@H]2O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5NC(C)=O)[C@H]4O)[C@H](O)[C@H]3NC(C)=O)[C@H]2O)[C@@H]1O

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.59
▸ LGALS8 O00214 1/20 0.59
▸ LGALS4 P56470 1/20 0.59
▸ CD69 Q07108 1/20 0.56
▸ CHIA Q9BZP6 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.53
▸ THRB P10828 1/20 0.53
▸ MAPK1 P28482 2/20 0.52
▸ LGALS1 P09382 1/20 0.49
▸ LGALS7; LGALS7B P47929 1/20 0.49
▸ LGALS9 O00182 1/20 0.48
▸ AMY2A P04746 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30655654 1.00 LGALS3 (0.59) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL30527817 1.00 LGALS3 (0.59) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL30570486 1.00 LGALS3 (0.59) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL30651312 1.00 LGALS3 (0.59) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL31701529 1.00 LGALS3 (0.59) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL31701532 1.00 LGALS3 (0.59) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL3244652 0.99 CD69 (0.57) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL3247667 0.99 CD69 (0.57) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL31453733 0.99 CD69 (0.57) LGALS3LGALS8LGALS4CD69CHIA
SCHEMBL15233925 0.99 CD69 (0.57) LGALS3LGALS8LGALS4CD69CHIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS APOB, APOL1, LDLR LGALS3 236/4885LGALS8 242/4885LGALS4 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback